MicroRNAs in pulmonary arterial hypertension: pathogenesis, diagnosis and treatment

• miRNAs are associated with the development of pulmonary arterial hypertension (PAH)
• The role of miRNAs in mechanisms associated with PAH is described and discussed
• Specific miRNAs previously associated with PAH are examined in detail
• Potential miRNA–based diagnostic and therapeutic approaches to PAH are examined

Pulmonary arterial hypertension (PAH) is a severe and increasingly prevalent disease, manifested by the maladaptation of pulmonary vasculature, which consequently leads to right heart failure and possibly even death. The development of PAH is characterized by specific functional as well as structural changes, primarily associated with the aberrant function of the pulmonary artery endothelial cells, smooth muscle cells, and vascular fibroblasts. MicroRNAs constitute a class of small ≈22–nucleotides–long non–coding RNAs that post–transcriptionally regulate gene expression and that may lead to significant cell proteome changes. While the involvement of miRNAs in the development of various diseases—especially cancer—has been reported, numerous miRNAs have also been associated with PAH onset, progression, or treatment responsiveness. This review focuses on the role of microRNAs in the development of PAH as well as on their potential use as biomarkers and therapeutic tools in both experimental PAH models and in humans. Special attention is given to the roles of miR–21, miR–27a, the miR–17–92 cluster, miR–124, miR–138, the miR–143/145 cluster, miR–150, miR–190, miR–204, miR–206, miR–210, miR–328, and the miR–424/503 cluster, specifically with the objective of providing greater insight into the pervasive roles of miRNAs in the pathogenesis of this deadly condition.

Figure optionsDownload high-quality image (287 K)Download as PowerPoint slide